3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Greece.
Curr Pharm Des. 2012;18(12):1605-8. doi: 10.2174/138161212799958585.
Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
谷氨酸是大脑中含量最丰富的兴奋性神经递质,离子型 NMDA 受体是其主要受体之一,被认为在精神分裂症和情绪障碍中发挥重要作用。本系统综述总结了 NMDA 受体参与双相情感障碍病理生理学的证据。遗传研究指向编码 NMDA 1、2A 和 2B 亚基的基因,而神经病理学研究表明,双相情感障碍患者 NMDA 受体的密度可能存在特定区域减少,更一致的是 NMDA 介导的谷氨酸能活性降低,这与 NMDA 动力学较慢有关,因为 NR2A 亚基的贡献较低。然而,文献资料匮乏且不完整;需要进一步的研究来阐明双相情感障碍的发病机制及其与 NMDA 功能障碍的特定关系,并探索开发新型治疗药物的可能性。